Active Bio and Teva’s laquinimod fails once more, now in Huntington’s disease

Teva
Laquinimod once carried blockbuster hopes as a potential heir to Copaxone in MS, but the phase 2 trial in Huntington's is the last study listed in Teva's pipeline. (Wikimedia Commons)

Active Biotech and Teva have delivered more bad news from their clinical development of laquinimod, this time from a phase 2 trial in Huntington’s disease.

The study did not meet its primary endpoint, comparing changes in motor skills after one year of treatment. It did, however, meet its secondary endpoint of reducing brain atrophy, and safety results were in line with expected events, the companies said in a statement. Active Bio’s stock fell 36% on the news, while Teva’s mostly held steady.

Once seen as a potential blockbuster heir to Copaxone in multiple sclerosis, and capable of generating up to $4 billion a year, Active Bio’s aryl hydrocarbon receptor activator would go on to see a series of disappointing efficacy results in later-phase trials, in both relapsing-remitting and primary progressive MS. Teva has held the rights to laquinimod’s commercialization and development since 2004.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The Huntington’s trial, the last listed for laquinimod in Teva’s pipeline, randomized 351 patients with an average age of about 44 years and compared three doses to placebo, at 0.5 mg, 1.0 mg and 1.5 mg daily. Patients were evaluated using the Unified Huntington's Disease Rating Scale - Total Motor Score.

RELATED: Teva, Active Biotech chalk up another phase 3 failure for once-hyped Copaxone heir laquinimod in multiple sclerosis

After cardiovascular safety concerns arose in a previous study of higher doses of laquinimod in MS, Teva discontinued the 1.5-mg arm as a precaution in January 2016, though no similar trends were seen in the Huntington’s study.

By the end, 287 patients had completed the study and 65 terminated early, including 30 who stopped when the 1.5-mg dose was halted.

RELATED: Active Bio and Teva’s laquinimod strikes out again, this time in progressive MS

Results were not released, but the data will continue to be analyzed, as Teva plans to submit the study for presentations at future medical meetings and for publication.

Suggested Articles

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.